LRRN3.md
... ...
@@ -24,12 +24,7 @@ timeline
24 24
25 25
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
26 26
27
-|Entity|source |frequency (%)|
28
-|:------:|:--------------:|:-------------:|
29
-|DLBCL |GAMBL genomes |8.22 |
30
-|DLBCL |Schmitz cohort|8.09 |
31
-|DLBCL |Reddy cohort |6.51 |
32
-|DLBCL |Chapuy cohort |6.84 |
27
+[[include:DLBCL_LRRN3.md]]
33 28
34 29
## Mutation pattern and selective pressure estimates
35 30
LTB.md
... ...
@@ -22,22 +22,15 @@ timeline
22 22
|Entity|Tier|Description |
23 23
|:------:|:----:|--------------------------------------|
24 24
|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@deschGenotypingCirculatingTumor2020]|
25
-|![DLBCL](images/icons/DLBCL_tier1.png) |1-a | aSHM target and high-confidence DLBCL gene [@chapuyMolecularSubtypesDiffuse2018]|
26
-|![FL](images/icons/FL_tier1.png) |1-a | aSHM target and high-confidence FL gene |
27
-|![BL](images/icons/BL_tier2.png) |2-a | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous [@paneaWholeGenomeLandscape2019]|
25
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@chapuyMolecularSubtypesDiffuse2018]|
26
+|![FL](images/icons/FL_tier1.png) |1 | aSHM target and high-confidence FL gene |
27
+|![BL](images/icons/BL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous [@paneaWholeGenomeLandscape2019]|
28 28
29 29
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
30 30
31
-|Entity|source |frequency (%)|
32
-|:------:|:---------------------:|:-------------:|
33
-|DLBCL |GAMBL genomes |9.37 |
34
-|DLBCL |Schmitz cohort |8.51 |
35
-|DLBCL |Reddy cohort | NA |
36
-|DLBCL |Chapuy cohort |9.83 |
37
-|FL |GAMBL genomes |8.78 |
38
-|BL |GAMBL genomes+capture|3.00 |
39
-|BL |Thomas cohort |3.00 |
40
-|BL |Panea cohort |5.90 |
31
+[[include:DLBCL_LTB.md]]
32
+[[include:FL_LTB.md]]
33
+[[include:BL_LTB.md]]
41 34
42 35
## Mutation pattern and selective pressure estimates
43 36
MEF2B.md
... ...
@@ -31,17 +31,8 @@ timeline
31 31
32 32
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
33 33
34
-|Entity|source |frequency (%)|
35
-|:------:|:---------------------:|:-------------:|
36
-|BL |GAMBL genomes+capture| 1.39 |
37
-|BL |Thomas cohort | 0.80 |
38
-|BL |Panea cohort | 3.00 |
39
-|DLBCL |GAMBL genomes |11.28 |
40
-|DLBCL |Schmitz cohort | 9.79 |
41
-|DLBCL |Reddy cohort | 5.91 |
42
-|DLBCL |Chapuy cohort | 5.56 |
43
-|FL |GAMBL genomes |12.93 |
44
-|MCL |GAMBL genomes | 5.69 |
34
+[[include:DLBCL_MEF2B.md]]
35
+[[include:FL_MEF2B.md]]
45 36
46 37
## Mutation pattern and selective pressure estimates
47 38